CAMZAVA Trademark

Trademark Overview

On Tuesday, June 16, 2020, a trademark application was filed for CAMZAVA with the United States Patent and Trademark Office. The USPTO has given the CAMZAVA trademark a serial number of 90002817. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 4, 2023. This trademark is owned by Sagent Pharmaceuticals, Inc.. The CAMZAVA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the treatment of chronic pancreatitis; oral serine protease inhibitor for the treatment of chronic pancreatitis
camzava

General Information

Serial Number90002817
Word MarkCAMZAVA
Filing DateTuesday, June 16, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 4, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 8, 2020

Trademark Statements

Goods and Servicespharmaceutical preparations for the treatment of chronic pancreatitis; oral serine protease inhibitor for the treatment of chronic pancreatitis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 13, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSagent Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSchaumburg, IL 60195
Party NameSagent Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSchaumburg, IL 60195

Trademark Events

Event DateEvent Description
Tuesday, September 5, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 4, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, March 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 29, 2023SOU EXTENSION 4 GRANTED
Thursday, February 2, 2023SOU EXTENSION 4 FILED
Monday, March 27, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, February 6, 2023NOTICE OF REVIVAL - E-MAILED
Monday, February 6, 2023SOU EXTENSION RECEIVED WITH TEAS PETITION
Monday, February 6, 2023PETITION TO REVIVE-GRANTED
Monday, February 6, 2023TEAS PETITION TO REVIVE RECEIVED
Wednesday, August 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 1, 2022SOU EXTENSION 3 GRANTED
Monday, August 1, 2022SOU EXTENSION 3 FILED
Monday, August 1, 2022SOU TEAS EXTENSION RECEIVED
Friday, December 24, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 22, 2021SOU EXTENSION 2 GRANTED
Wednesday, December 22, 2021SOU EXTENSION 2 FILED
Wednesday, December 22, 2021SOU TEAS EXTENSION RECEIVED
Friday, July 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 14, 2021SOU EXTENSION 1 GRANTED
Wednesday, July 14, 2021SOU EXTENSION 1 FILED
Wednesday, July 14, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, February 2, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 8, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 8, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 18, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, November 2, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, September 25, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 25, 2020NON-FINAL ACTION E-MAILED
Friday, September 25, 2020NON-FINAL ACTION WRITTEN
Friday, September 18, 2020ASSIGNED TO EXAMINER
Monday, July 13, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 19, 2020NEW APPLICATION ENTERED

Related Keywords

camzava chronic treatment pancreatitis protease inhibitor serine oral pharmaceutical preparations